Hormone therapy and precise radiation for intermediate-risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of prostate cancer called 'unfavorable intermediate-risk' as defined by your doctor.
- You need to have had a Decipher genomic test on your tumor.
- You must have a visible tumor on MRI that scored as PI-RADS 4 or 5.
- You need to have had a PSMA PET/CT scan to check for cancer spread.
- Your testosterone level must be within normal range (≥150 ng/dL).
- You cannot have had prior pelvic radiation or a history of seizures or certain serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
This trial tests a precise radiation technique that adapts to your body's daily changes. It may offer better outcomes for men with prostate cancer that hasn't spread outside the pelvic area.
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.